Glucose transporter type 1 deficiency syndrome (Glut1 DS) is a rare neurological disorder caused by impaired glucose delivery to the brain. The clinical spectrum of Glut1 DS mainly includes epilepsy, paroxysmal dyskinesia (PD), developmental delay and microcephaly. Glut1 DS diagnosis is based on the identification of hypoglycorrhachia and pathogenic mutations of the SLC2A1 gene. Here, we report the molecular screening of SLC2A1 in 354 patients clinically suspected for Glut1 DS. From this cohort, we selected 245 patients for whom comprehensive clinical and laboratory data were available. Among them, we identified 19 patients carrying nucleotide variants of pathological significance, 5 of which were novel. The symptoms of onset, which varied from neonatal to adult age, included epilepsy, PD or non-epileptic paroxysmal manifestations. The comparison of the clinical features between the 19 SLC2A1 mutated and the 226 non-mutated patients revealed that the onset of epilepsy within the first year of life (when associated with developmental delay or other neurological manifestations), the association of epilepsy with PD and acquired microcephaly are more common in mutated subjects. Taken together, these data confirm the variability of expression of the phenotypes associated with mutation of SLC2A1 and provide useful clinical tools for the early identification of subjects highly suspected for the disease.
Introduction
Glucose transporter type 1 deficiency syndrome (Glut1 DS, OMIM 606777) is a rare neurological disorder caused by impaired glucose delivery to the brain [1] . It results from haploinsufficiency of the SLC2A1 gene encoding Glut1, the main protein responsible for glucose transport across the blood-brain barrier [2] . It was first described in patients presenting with infantile seizures, developmental delay, acquired microcephaly, persistent hypoglycorrhachia and a complex movement disorder consisting of ataxia and spasticity [1] . Since then, the clinical spectrum associated with Glut1 DS has been extensively broadened and over the years many other clinical manifestations have been described, such as paroxysmal dyskinesia (PD) with or without epilepsy, alternating hemiplegia, and migraine [3, 4] .
Epilepsy is present in approximately 90% of patients [5] and, beyond the classic drug-resistant infantile seizures, the epileptic phenotype includes both focal and generalized epilepsies. Several authors have recently shown that 10% of early-onset absence epilepsies [6, 7] , 5% of myoclonicastatic epilepsies [8] and 1% of idiopathic generalized epilepsies [9] are caused by mutations of the SLC2A1 gene, although these results were not confirmed by subsequent studies [10, 11] .
Diagnosis is confirmed by the evidence of hypoglycorrhachia [12] and loss-of-function mutations in the SLC2A1 gene. Providing an early diagnosis is crucial for patients, as it allows a prompt initiation of the ketogenic diet, which has been proved effective in the management of seizures and movement disorders in Glut1 DS patients [13, 14] .
We performed the genetic analysis of SLC2A1 gene in 354 patients clinically suspected for Glut1 DS, and identified the presence of nucleotide variants of pathological significance in 19 subjects. The aims of our study were: (1) to summarize the clinical characteristics of 19 patients carrying SLC2A1 mutations, (2) to describe the clinical features of 5 patients carrying novel mutations and (3) to compare the clinical characteristics of mutated patients with those of non-mutated.
Patients and methods

Ethical issues
Biological samples from patients and their relatives were obtained for analysis, research and storage, after the acquisition of written informed consent according to international guidelines and approved by the Internal Institutional Ethics Committee.
All human studies have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Patients
We retrospectively reviewed all the patients who underwent the genetic screening of SLC2A1 in our Institution between January 2005 and December 2016. The analysis was requested according to the suspicions of Glut1 DS, for one or more of the following indications: epilepsy, PD or other non-epileptic paroxysmal events. The molecular screening of SLC2A1 was carried out in 354 patients. From this cohort, we selected 245 patients for whom clinical and laboratory data were fully available. From our in house database, we collected the following information: gender, age at Glut1 DS diagnosis, characteristics of the epileptic features (including age of onset, seizure type and EEG characteristics), drug resistance, paroxysmal dyskinesia (onset and type), other symptoms (onset and diagnosis at the clinical observation), CSF data (CSF glucose/glycemia ratio) and genetic data (result of the SLC2A1 gene screening).
Molecular studies
Genomic DNA was extracted from peripheral blood lymphocytes, according to standard procedures. Written informed consent for DNA analysis was obtained from all patients and family members. DNA samples were screened for mutations in the SLC2A1 gene (exons 1-10). Exons and intron-exon boundaries were analyzed by direct sequence analysis using an automated sequencing system (ABI 3130 XL). The primers are available on request. Patients negative for point mutations in the gene, with hypoglycorrhachia and/or the presence of common polymorphisms in homozygous condition indicating a possible presence of a heterozygous deletion, were also screened for exon deletion or duplication by multiplex ligation-dependent probe amplification (MLPA). MLPA was performed using the SALSA MLPA kit P138-SLC2A1 (MRC-Holland). We have also performed segregation analysis in parents of patients carrying variants in SLC2A1 gene. Only in patient # 19 parents' DNA was not available for segregation studies.
Nucleotides and amino acid residues were numbered according to the reference gene sequence of the transcript GenBank (NCBI): SLC2A1 (Homo sapiens NM_006516, NP_006507). Sequence variations and predicted protein changes were described according to nomenclature recommendations (http://www.hgvs.org/mutno men/recs.html). Segregation of genetic variants was analyzed through validation in all available family members. Frequencies of novel missense variants were determined by comparison with The Human Gene Mutation Database (http://www.hgmd.cf.ac. uk/ac/index .php), the NCBI dbSNP132ver (http://www.ncbi. nlm.nih.gov/proje cts/SNP/) and the Exome Variant Server (http://evs.gs.washi ngton .edu/EVS/). In silico analysis of missense variants was performed using the PolyPhen-2 (http://genet ics.bwh.harva rd.edu/pph2/), and SIFT prediction test (http://sift.jcvi.org/). ASSP algorithm (http://wangc omput ing.com/assp/) was used for alternative splice site prediction as the novel variant occurred close to the 5′ splice site, and ESE Finder Software 3.0 (http://rulai .cshl.edu/ 1 3 cgi-bin/tools /ESE3/esefi nder.cgi?proce ss=home) for evaluating the disruption of putative exonic splicing enhancers (ESEs), which are binding sites for human SR proteins SF2/ ASF, SC35, SRp40 and SRp55.
Statistical analysis
Statistical analysis was conducted using STATA/IC version 15. Descriptive statistics were expressed as means and standard deviations for continuous variables and as percentages for categorical variables. Comparisons of continuous data were performed with t test and those of categorical data with chi-squared test or Fisher's exact test. Variables that were found to be statistically significant were analyzed using the logistic regression. A p value ≤ 0.05 was considered statistically significant.
Results
From January 2005 to December 2016, 354 patients were analyzed by SLC2A1 sequencing. We detected sequence variants in 19 patients, belonging to 18 families (5.4%), and 5 of these variants were novel (Table 1) .
Clinical features of the 19 SLC2A1-mutated patients
The presenting symptom or the reason for referring was epilepsy in 16 patients (84.2%) and movement disorders in 3. The mean age at molecular analysis was 16.0 ± 7.6 years. The series includes 17 sporadic cases and 1 familial case. Fifteen out of the 17 sporadic cases carried a de novo variant (i.e. not present in parents), in one patient (# 19) parents' DNA was not available for segregation studies and in one patient (#12) the identified variant was also present in the asymptomatic father. One case was familial because the identified variant was present in the proband and in her symptomatic father (#15 and #16). All patients were born to non-consanguineous parents; pregnancy, delivery and the neonatal period were uneventful in all. Clinical, biochemical and genetic features of patients are detailed in Table 1 . Patients #4, 5, 11, 17 have been already reported [15, 16] . The clinical features of the five patients carrying SLC2A1 novel variants are reported in the Supplementary material.
Patients presenting with seizures
The mean age at seizure onset was 2.4 years (range 2 months-9 years). Eight patients (#1-7, 15) had epilepsy onset in the first year of life characterized by myoclonic (6 infants), convulsive (1), or focal seizures (1) . At the time of epilepsy onset, all these patients had other symptoms (i.e. developmental delay, or abnormalities of eye movements, or hypotonia).
In 8 patients (#8-14, 16), epilepsy onset was after the first year of age. The absence was the most common seizure type (seven cases), preceded by febrile seizures in two children. One patient had focal seizures. At the onset of epilepsy, the large majority of patients had associated symptoms: intellectual disabilities of various degree or specific learning disability, microcephaly, headache, dystonia, spasticity and ataxia. In six patients, seizure frequency was increased by fasting. During the course of the disease, paroxysmal dyskinesia appeared in 10 out of the 16 patients with epilepsy, after a mean interval of 5.9 ± 2.2 years. PD featured as PED in seven patients, as PNKD in two and as PKD in one. At molecular diagnosis, all the mutated patients had a complex clinical picture characterized by the association of epilepsy with at least one of the following symptoms: MD, microcephaly, headache, ataxia, myoclonus, spasticity, dystonia and intellectual disability of various severity.
Patients presenting with movement disorders
Paroxysmal movement disorder was the first symptom in three patients (PED in two and PNKD in one), with an age at onset ranging between 4 and 13 years (# 14-16). In all cases, symptoms worsened by fasting. Additional features, variably associated in the different patients (see Table 1 ) were microcephaly, headache intellectual disability, ataxia, spasticity and dystonia. None of these patients experienced epileptic seizures during the disease course (present age ranging from 21 to 42 years).
Clinical features of the 226 SLC2A1-non-mutated patients
The mean age at molecular analysis was 12.5 ± 11.8 years. The main reason for referring was epilepsy (168 patients) that was associated with PD in 9. In most patients with epilepsy as a prominent symptom, the onset of seizure was after the first year of life (135 patients). Two out of these patients experienced PD during the follow-up. Epilepsy was characterized by generalized seizures with absences and/or myoclonic seizures, associated with diffuse spikes and waves at in 96 patients and by generalized or focal seizures without spike and waves in 37. Thirty-three patients (14.5%) were referred for epilepsy which had started within the first year of life, either as epileptic encephalopathy, or myoclonic or focal epilepsy. In 73% of patients, epilepsy was associated with developmental delay and with PD in seven.
Twenty-nine patients underwent genetic analysis for the presence of PD, and 17 for other non-epileptic paroxysmal events such as headache, alternating hemiplegia, episodic ataxia. Finally, in 12 patients, the genetic analysis was 
Comparison between mutated and non-mutated patients
We compared the clinical pictures of the 19 SLC2A1-mutated patients from 18 families with those of the 226 non-mutated patients (Table 2) . No statistically significant differences were found in the two groups with regard to gender, mean age at the time of genetic analysis, family history for epilepsy or movement disorders and developmental delay. At the time of genetic testing, there was a significantly high proportion of patients with acquired microcephaly in mutated patients (47.4% vs 13.7%, p < 0.0001; OR 5.6; 95% CI 2.1-15; p = 0.001). Epilepsy was the most common symptom in both mutated (84.2%) and non-mutated patients (74.3%). Seizures were mostly generalized and were drug resistant in a similar proportion of patients in both groups. The mean age at onset of epilepsy in mutated patients was lower than in non-mutated (2.4 vs 4.9 years), although this difference did not reach a statistical significance. Nonetheless, there was a significantly different proportion of patients with onset of epilepsy in the first year of life: seizures started within the first year in 8/16 mutated patients and in 33/168 non-mutated patients (50% vs 19.6% p < 0.005; OR 21.8; 95% CI 6.0-79.3; p < 0.001).
Thirty-eight patients underwent molecular analysis in the diagnostic work-up for PD, either occurring as an isolated symptom or associated with epilepsy. Isolated PD, which had a similar age of onset in the two groups, was found in 15.7% of mutated patients and in 12.8% of non-mutated. In contrast, the association of epilepsy and PD was found in higher proportion among SLC2A1-mutated patients than in non-mutated (57.9% versus 3.98%, %, p < 0.0001; OR 33.1; 95% CI 10.7-102.5; p < 0.001).
Discussion
We report the analysis of the clinical and molecular finding in a large series of patients who underwent SLC2A1 genetic screening.
As soon as our Lab was able to perform mutational analysis of SLC2A1 gene, we received a large amount of DNA samples to be analyzed, both from our Institution and from other referring centers. It is likely that in a number of cases, the indication to the analysis was simply the search for a treatable disorder and in other the hope for a solution in unsolved and complex cases. This "enlarged indication" probably explains the low ratio (19/354) of confirmed diagnosis of a disease, that still remains extremely rare. Within this cohort, we identified 19 patients from 18 families carrying variants of pathological significance (previously described) or of possible pathological significance (novel variants). To define the indications for molecular analysis of the gene, we compared clinical features of mutated and non-mutated patients.
Patients carrying mutations
The analysis of the clinical features of the patients carrying SLC2A1 gene variants confirms the wide clinical spectrum associated with Glut1 defects [17] . In our cohort, in line with previous reports, epilepsy was the most frequent presenting symptom. In a few patients, spontaneous seizures had been preceded by "febrile convulsions". This suggests that, beside fasting, fever might also be considered as a trigger factor for seizures, at least during infancy. Further unusual symptoms were fatigue-and food-related disorders, such as feeling hunger and compulsory eating (with ensuing overweight), which may mask the classical worsening of symptoms during fasting.
In our cohort, paroxysmal dyskinesia was present in 12/19 mutated patients, and, in line with literature data [17] , featured as PED in most cases. A minority of patients, however, experienced PNKD and PKD. These latter cases, together with the few previously reported [18] , widen the spectrum of paroxysmal dyskinesia in Glut1 DS, and confirm that all types of paroxysmal dyskinesia should be considered among the key symptoms of the disease. Paroxysmal dyskinesia appeared in 10 out of the 16 patients with epilepsy, during the follow-up (after a mean interval of 5.9 ± 2.2 years); whereas, it was the presenting symptom in 3 patients. Interestingly, in our series, when PD was the presenting symptom, its onset was in late childhood or adolescence and no seizure appeared during the prolonged follow-up.
Beside epilepsy and PD, which were the prominent symptoms, further paroxysmal symptoms varied according to the different ages. In infants, paroxysmal ocular movements might precede the onset of epilepsy; these abnormal movements had been frequently misdiagnosed as focal seizures. In contrast, in late childhood, adolescence and adulthood, headache was the most frequent paroxysmal symptom. Non-paroxysmal symptoms which included acquired microcephaly, intellectual disability of various degree, and motor deficits (ataxia, spasticity, dystonia) of variable severity were present in the majority of patients.
Comparing mutated and non-mutated patients
We compared the clinical features in the 19 mutated and in the 226 non-mutated patients. By the comparison between these two cohorts, it emerged that (1) the presence of epilepsy with onset within the first year of life, particularly when associated with developmental delay or other neurological manifestations, (2) the association of epilepsy with PD and (3) acquired microcephaly, is significantly more common in mutated patients. In fact, even if these three symptoms per se are not pathognomonic of the disease, their combined presence may suggest the diagnosis of Glut1 DS and rapidly lead to the procedures necessary to confirm the diagnostic suspect, including the genetic analysis of SLC2A1 gene. 
Conclusions
The analysis of SLC2A1 gene in a large series of patients referred to our Lab allowed to identify novel variants of possible pathological significance. The predictive characteristics (in silico analysis) of these novel variants and the segregation in the families of the probands support their causative role in the disease. Glut1 deficiency has been reported to underlie genetic generalized epilepsies and, therefore, this diagnosis must be considered in all familial epilepsies [9, 19, 20] .
However, in line with previous reports and reviews, our data confirm that Glut1 DS is a multi-symptomatic disorder, albeit with a wide spectrum of expressivity. In sporadic cases (which are the vast majority of the study cohort reported in this paper), Glut1 DS should be strongly suspected only in patients presenting with epilepsy associated with at least one of the following: microcephaly, movement disorders including all the three types of paroxysmal dyskinesia, psychomotor delay/ intellectual disability, or one of the less common symptoms reported above. By contrast, Glut1 DS is extremely unlikely in patients featuring isolated epilepsy or isolated movement disorder [10, 15, 21] .
